Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7322
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    83.82
    +0.25 (+0.30%)
     

  • Bitcoin CAD

    88,015.04
    +320.57 (+0.37%)
     

  • CMC Crypto 200

    1,392.67
    +10.10 (+0.73%)
     

  • GOLD FUTURES

    2,346.10
    +3.60 (+0.15%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,772.75
    +205.25 (+1.17%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,803.41
    +174.93 (+0.46%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

Quantum eMotion Sentry-Q platform to be used in Greybox Solutions digital therapeutics

News Direct
·1 min read

New York, New York --News Direct-- Quantum eMotion Corp

Quantum eMotion CEO Francis Bellido joins Natalie Stoberman from the Proactive studio to discuss the latest Sentry-Q platform commercial agreement with Greybox Solutions, a Montreal-based health technology company specializing in innovative software development to improve patients' lives.

Bellido says this partnership will enable Greybox's TakeCare digital therapeutic product to take advantage of QeM's Quantum-Safe cryptographic platform. Digital therapeutics refers to the use of technology-driven solutions, such as mobile apps, wearable devices, and telemedicine, to enhance patient outcomes by leveraging the benefits of technology such as patient health records convenience, accessibility, and real-time monitoring and feedback.

Proactive United States Finance News

Contact Details

Proactive USA

ADVERTISEMENT

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/quantum-emotion-sentry-q-platform-to-be-used-in-greybox-solutions-digital-therapeutics-104813660